Transcript of Speech and Q&A Conference Call Q2 - MorphoSys
Transcript of Speech and Q&A Conference Call Q2 - MorphoSys
Transcript of Speech and Q&A Conference Call Q2 - MorphoSys
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
arthritis patients. Meanwhile, development <strong>of</strong> CNTO1959 in psoriasis continues in separate<br />
Phase 1 <strong>and</strong> 2 trials.<br />
Slide 9: AbD Serotec<br />
I’ll conclude my operational review with AbD Serotec. The research market, which is heavily<br />
dependent on public research funding, continues to be challenging <strong>and</strong> this is reflected in<br />
AbD’s results this quarter. This is one <strong>of</strong> the reasons why the focus is increasingly on<br />
diagnostics <strong>and</strong> larger technology <strong>and</strong>/or collaborative transactions. We see these larger<br />
opportunities as being the main drivers <strong>of</strong> both revenue <strong>and</strong> pr<strong>of</strong>it for AbD for the remainder<br />
<strong>of</strong> the year. Meanwhile, we continue to focus on anti-drug-antibodies, where our HuCAL<br />
technology is particularly suited. The first products are already available: antibodies against<br />
Rituxan ® , Herceptin ® , Campath ® , <strong>and</strong> Avastin ® . New products for determination <strong>of</strong> Humira ® ,<br />
Stelara ® , <strong>and</strong> Remicade ® will follow shortly.<br />
That concludes my review <strong>of</strong> the quarter. I’d now like to h<strong>and</strong> over to Jens for the financial<br />
update.<br />
<strong>MorphoSys</strong> AG <strong>Q2</strong> 2012 <strong>Conference</strong> <strong>Call</strong> Manuscript Page 4 <strong>of</strong> 17
Change language